

PUBLIC ANNOUNCEMENT



(Please scan the QR Code to view the DRHP)



Patient First

JUPITER LIFE LINE HOSPITALS LIMITED

Our Company was incorporated as 'Jupiter Life Line Hospitals Limited' at Mumbai, Maharashtra as a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 18, 2002, issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"). Our Company commenced its business on December 24, 2002. For further details on the changes in the registered office of our Company, see "History and Certain Corporate Matters" on page 213 of the Draft Red Herring Prospectus dated May 10, 2023 ("DRHP"), filed with the Securities and Exchange Board of India ("SEBI") and the Stock Exchanges on May 11, 2023.

Corporate Identity Number: U85100MH2002PLC137908; **Website:** www.jupiterhospital.com

Registered Office: 1004, 10th Floor, 360 Degree Business Park, Maharana Pratap Chowk, LBS Marg, Mulund (West), Mumbai – 400 080, Maharashtra, India

Corporate Office: Jupiter Hospital, Eastern Express Highway, Thane (West), Mumbai – 400 601 Maharashtra, India

Contact Person: Suma Upparatti, Company Secretary and Compliance Officer; **Telephone:** +91 22 2172 5623; **Email:** cs@jupiterhospital.com

OUR PROMOTERS: DR. AJAY THAKKER, DR. ANKIT THAKKER AND WESTERN MEDICAL SOLUTIONS LLP

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹10 EACH OF OUR COMPANY ("EQUITY SHARES") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 6,150.00 MILLION ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 4,450,000 EQUITY SHARES ("OFFERED SHARES") AGGREGATING UP TO ₹ [●] MILLION COMPRISING UP TO 1,250,000 EQUITY SHARES BY DEVANG VASANTLAL GANDHI (HUF) AGGREGATING UP TO ₹ [●] MILLION, UP TO 900,000 EQUITY SHARES BY DEVANG GANDHI JOINTLY WITH NEETA GANDHI AGGREGATING UP TO ₹ [●] MILLION, UP TO 1,000,000 EQUITY SHARES BY NITIN THAKKER JOINTLY WITH ASHA THAKKER AGGREGATING UP TO ₹ [●] MILLION, UP TO 400,000 EQUITY SHARES BY ANURADHA RAMESH MODI WITH MEGHA RAMESH MODI (AS TRUSTEES FOR THE BENEFIT OF MODI FAMILY PRIVATE TRUST) AGGREGATING UP TO ₹ [●] MILLION, UP TO 400,000 EQUITY SHARES BY BHASKAR P SHAH (HUF) AGGREGATING UP TO ₹ [●] MILLION, UP TO 200,000 EQUITY SHARES BY RAJESHWARI CAPITAL MARKET LIMITED AGGREGATING UP TO ₹ [●] MILLION, UP TO 200,000 EQUITY SHARES BY VADAPATRA SAYEE RAGHAVAN (HUF) AGGREGATING UP TO ₹ [●] MILLION, UP TO 40,000 EQUITY SHARES BY SANGEETA RAVAT JOINTLY WITH DR. HASMUKH RAVAT AGGREGATING UP TO ₹ [●] MILLION, UP TO 40,000 EQUITY SHARES BY DR. HASMUKH RAVAT JOINTLY WITH SANGEETA RAVAT AGGREGATING UP TO ₹ [●] MILLION AND UP TO 20,000 EQUITY SHARES BY SHREYAS RAVAT JOINTLY WITH SANGEETA RAVAT AGGREGATING UP TO ₹ [●] MILLION (TOGETHER, THE "SELLING SHAREHOLDERS", AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE"). THE OFFER SHALL CONSTITUTE [●]% OF THE POST-OFFER PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10 EACH. THE OFFER PRICE IS [●] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY AND THE SELLING SHAREHOLDERS IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS AND WILL BE ADVERTISED IN ALL EDITIONS OF THE FINANCIAL EXPRESS (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), ALL EDITIONS OF JANSATTA (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND THE MUMBAI EDITION OF NAVSHAKTI (A WIDELY CIRCULATED MARATHI DAILY NEWSPAPER, MARATHI BEING THE REGIONAL LANGUAGE OF MAHARASHTRA WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID / OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE", AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") FOR UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI CDR REGULATIONS").

PUBLIC ANNOUNCEMENT TO THE DRAFT RED HERRING PROSPECTUS DATED MAY 10, 2023 (THE "PUBLIC ANNOUNCEMENT")

This is in relation to the directive dated July 4, 2023, issued through an e-mail from the Securities and Exchange Board of India ("SEBI") pursuant to which, we are required to intimate the National Stock Exchange of India Limited ("NSE") and the BSE Limited ("BSE") and along with the NSE, the "Stock Exchanges" and make a public announcement in an English national daily newspaper, a Hindi national daily newspaper and a regional language newspaper in the event our Company undertakes a pre-IPO placement.

Our Company, in consultation with the BRLMs, was considering a further issue of specified securities, to any person(s) for cash consideration aggregating up to ₹ 1,230.00 million, at its discretion prior to filing of the Red Herring Prospectus with the RoC ("Pre-IPO Placement"). Pursuant to such authorization, on August 16, 2023, the Company undertook the Pre-IPO Placement of 1,673,469 Equity Shares aggregating to ₹ 1,229.99 million, at a price of ₹ 735 per Equity Share to the following allottees ("Investors"):

Date of allotment	Name of the allottee	Number of Equity Shares	Face value per Equity Share (in ₹)	Issue price per Equity Share (in ₹)
August 19, 2023	SBI Magnum Children's Benefit Fund - Investment Plan	541,497	10	735
	Neuberger Berman Emerging Markets Equity Fund	268,186	10	735
	SBI Healthcare Opportunities Fund	200,000	10	735
	High Conviction Fund - Series 1	149,660	10	735
	Ashoka India Equity Investment Trust PLC	149,660	10	735
	Think India Opportunities Master Fund LP	149,660	10	735
	DC Ikka Limited	122,448	10	735
	SBI Optimal Equity Fund	74,830	10	735
	Neuberger Berman Europe Holdings LLC	7,735	10	735
	Neuberger Berman Strategic India Equity Master Fund Holdings Limited	9,793	10	735

We further confirm and declare that the Investors are not, in any manner, connected with our Company, our Promoters, members of our Promoter Group, our Directors, our Key Managerial Personnel, our Subsidiaries and our Group Companies and their respective directors and key managerial personnel.

BOOK RUNNING LEAD MANAGERS			REGISTRAR TO THE OFFER
ICICI Securities Limited ICICI Venture House, Appasaheb Marathe Marg Prabhadevi, Mumbai 400 025, Maharashtra, India Telephone: +91 22 6807 7100 Email: jupiterhospital.ipo@icicisecurities.com Investor grievance email: customercare@icicisecurities.com Website: www.icicisecurities.com Contact person: Sameer Purohit/ Gaurav Mittal SEBI registration no: INM000011179	Nuvama Wealth Management Limited^A (formerly known as Edelweiss Securities Limited) 801 - 804, Wing A, Building No 3, Inspire BKC, G Block Bandra Kurla Complex, Bandra East, Mumbai - 400 051 Maharashtra, India Telephone: +91 22 4009 4400 Email: Jupiterhospitals.ipo@nuvama.com Investor grievance email: customerservice.mb@nuvama.com Website: www.nuvama.com Contact person: Manish Tejwani SEBI registration no: INM000013004	JM Financial Limited 7th Floor, Cnergy, Appasaheb Marathe Marg Prabhadevi, Mumbai 400 025 Maharashtra, India Telephone: + 91 22 6630 3030 Email: jupiterhospital.ipo@jmf.com Investor grievance email: grievance.ibd@jmf.com Website: www.jmf.com Contact person: Prachee Dhuri SEBI registration no: INM000010361	KFin Technologies Limited Selenium Tower B, Plot No. 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad, - 500 032 Telangana, India Telephone: +91 40 6716 2222 Email: jupiterlife.ipo@kfintech.com Investor grievance email: einward.ris@kfintech.com Website: www.kfintech.com Contact person: M Murali Krishna SEBI registration no: INR000000221

^APursuant to an order passed by Hon'ble National Company Law Tribunal, Mumbai Bench dated April 27, 2023, the merchant banking business of Edelweiss Financial Services Limited has demerged and is now transferred to Nuvama Wealth Management Limited ("Nuvama") and therefore the said merchant banking business is part of Nuvama.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For JUPITER LIFE LINE HOSPITALS LIMITED

On behalf of the Board of Directors

Sd/-

Suma Upparatti

Company Secretary and Compliance Officer

Place : Mumbai

Date : August 21, 2023

JUPITER LIFE LINE HOSPITALS LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offer of its Equity Shares and has filed the DRHP dated May 10, 2023 with SEBI on May 11, 2023. The DRHP is available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e., BSE at www.bseindia.com and NSE at www.nseindia.com and is available on the websites of the BRLMs, i.e. ICICI Securities Limited at : www.icicisecurities.com, Nuvama Wealth Management Limited at : www.nuvama.com and JM Financial Limited at www.jmf.com. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section titled "Risk Factors" of the RHP, when filed. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision. Specific attention of the investors is invited to "Risk Factors" beginning on page 32 of the DRHP.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) outside the United States, to investors in "offshore transactions" as defined in and in reliance on Regulation S (under the U.S. Securities Act) and the applicable laws of the jurisdictions where the Offer and sales occur and (ii) within the United States, only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) in one or more private transactions exempt from the registration requirements under the U.S. Securities Act. There will be no offering in the United States.